Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
View Patent ↗This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating stress disorders. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating stress disorders in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
1. A method of ameliorating the symptoms of a stress disorder in a patient in need thereof by administration of an amount of a glucocorticoid receptor antagonist effective to ameliorate the symptoms of the stress disorder, wherein the stress disorder is selected from the group consisting of Acute Stress Disorder and Brief Psychotic Disorder With Marked Stressor(s), with the proviso that the patient be not otherwise in need of treatment with a glucocorticoid receptor antagonist.
2. The method of claim 1 , wherein the glucocorticoid receptor antagonist comprises a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton.
3. The method of claim 2 , wherein the phenyl-containing moiety in the 11-beta position of the steroidal skeleton is a dimethylaminophenyl moiety.
4. The method of claim 3 , wherein the glucocorticoid receptor antagonist comprises mifepristone.
5. The method of claim 4 , wherein the glucocorticoid receptor antagonist is selected from the group consisting of RU009 and RU044.
6. The method of claim 1 , wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 0.5 to about 20 mg per kilogram of body weight per day.
7. The method of claim 6 , wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 1 to about 10 mg per kilogram of body weight per day.
8. The method of claim 7 , wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 1 to about 4 mg per kilogram of body weight per day.
9. The method of claim 1 , wherein the administration is once per day.
10. The method of claim 1 , wherein the mode of administration is oral.
11. The method of claim 1 , wherein the mode of administration is by a transdermal application, by a nebulized suspension, or by an aerosol spray.
12. A method of ameliorating the emergence of stress disorder symptoms in a patient exposed to a traumatic stressor, the method comprising administering an effective amount of a glucocorticoid receptor antagonist to the patient within 30 days of exposure to the traumatic stressor.
13. The method of claim 1 wherein the stress disorder is Acute Stress Disorder.
14. The method of claim 1 wherein the stress disorder is Brief Psychotic Disorder With Marked Stressor(s).
15. A method of reducing the symptoms of a stress disorder in a patient in need thereof by administration of an amount of a glucocorticoid receptor antagonist effective to ameliorate the symptoms of the stress disorder, wherein the stress disorder is selected from the group consisting of Acute Stress Disorder and Brief Psychotic Disorder With Marked Stressor(s), with the proviso that the patient be not otherwise in need of treatment with a glucocorticoid receptor antagonist.
16. The method of claim 15 wherein administration is given within 30 days of exposure to a traumatic stressor.